Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Deloitte
Fuji
Express Scripts
Healthtrust
US Department of Justice

Generated: August 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 10,166,184

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,166,184 protect, and when does it expire?

Patent 10,166,184 protects VYXEOS and is included in one NDA.

This patent has eighteen patent family members in eleven countries.

Summary for Patent: 10,166,184
Title:Method of lyophilizing liposomes
Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.
Inventor(s): Cabral-Lilly; Donna (Pennington, NJ), Mayer; Lawrence (North Vancouver, CA), Tardi; Paul (Surrey, CA), Watkins; David (East Greenwich, RI), Zeng; Yi (Somerset, NJ)
Assignee: CELATOR PHARMACEUTICALS INC. (Ewing, NJ)
Application Number:15/891,170
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 10,166,184

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Celator Pharms VYXEOS cytarabine; daunorubicin POWDER;INTRAVENOUS 209401-001 Aug 3, 2017 RX Yes Yes   Try a Free Trial   Try a Free Trial Y METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 10,166,184

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2012326370   Try a Free Trial
Brazil 112014009305   Try a Free Trial
Canada 2852777   Try a Free Trial
China 104114156   Try a Free Trial
China 108853031   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
AstraZeneca
Moodys
Mallinckrodt
Chubb
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.